Prescription medicine
Desloratadine and pseudoephedrine Brand names: Clarinex-D; first approved as Clarinex D 24 Hour
Desloratadine and pseudoephedrine (Clarinex-D) is a prescription medicine with an FDA approval on record since 2005. No generic is listed; pharmacies paid $6.07 per Clarinex-d 12 hr 2.5-120 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the desloratadine and pseudoephedrine FDA label on DailyMed (effective November 12, 2025); the NDA 21605 record on Drugs@FDA; every desloratadine and pseudoephedrine label on DailyMed.
Highlights of the record
FDA label of November 12, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCLARINEX-D 12 HOUR is a combination product containing a histamine-1 (H1) receptor antagonist and an alpha adrenergic agonist indicated for: Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older.
Forms and strengths
- 2.5 mg / 120 mg
Extended-release tablet.
On the market
- Earliest approval on file
- March 3, 2005 Clarinex D 24 Hour, Organon; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first April 26, 2011; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $6.07 per tablet Clarinex-d 12 hr 2.5-120 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 39 through July 30, 2026
What is desloratadine and pseudoephedrine used for?
From the label: indications and usageCLARINEX-D 12 HOUR is a combination product containing a histamine-1 (H1) receptor antagonist and an alpha adrenergic agonist indicated for: Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. ( 1.1 ) 1.1 Seasonal Allergic Rhinitis CLARINEX-D ® 12 HOUR Extended Release Tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. […]
Conditions named in the indications of desloratadine and pseudoephedrine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Histamine-1 Receptor Antagonist and alpha-Adrenergic Agonist.
Source: FDA drug label (CLARINEX-D 12 HOUR), Organon LLC, effective November 12, 2025 (SPL set 1af66b7a-4ab8-40d8-abdd-22d3310228a8), via openFDA; the full label on DailyMed
Is there a generic for desloratadine and pseudoephedrine (Clarinex-D)?
The FDA approved the first generic desloratadine and pseudoephedrine on April 26, 2011. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
- 2005 earliest approval on file
- 2011 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for desloratadine and pseudoephedrine (Clarinex-D)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $6.07 per Clarinex-d 12 hr 2.5-120 mg tablet, up 5% from $5.78 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Clarinex-d 12 hr 2.5-120 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Clarinex-d 12 hr 2.5-120 mg tablet | Brand | $6.07 per tablet | $182.05 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the desloratadine and pseudoephedrine label say about other medicines?
The desloratadine and pseudoephedrine label names 7 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Azithromycin | drug interactions | Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of … |
| Cimetidine | drug interactions | In controlled clinical studies co-administration of desloratadine with cimetidine a histamine H 2 -receptor antagonist resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine [see Clinical Pharmacology … |
| Erythromycin | drug interactions | Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of … |
| Fluoxetine | drug interactions | In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine [see Clinical … |
| Ketoconazole | drug interactions | Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of … |
| Loratadine | contraindications | CONTRAINDICATIONS CLARINEX-D 12 HOUR Extended Release Tablets are contraindicated in: Patients with hypersensitivity to any of its ingredients, or to loratadine [see Warnings and Precautions (5.4) and Adverse Reactions (6.2) ] Patients with narrow-angle glaucoma Patients with urinary retention Patients receiving … |
| Methyldopa | drug interactions | The antihypertensive effects of beta-adrenergic blocking agents, methyldopa, and reserpine, may be reduced by sympathomimetics such as pseudoephedrine. |
Check desloratadine and pseudoephedrine against other medicines
Source: FDA drug label (CLARINEX-D 12 HOUR), Organon LLC, effective November 12, 2025 (SPL set 1af66b7a-4ab8-40d8-abdd-22d3310228a8), via openFDA; the full label on DailyMed
What do FAERS reports show for desloratadine and pseudoephedrine?
The FDA Adverse Event Reporting System holds 39 reports that list desloratadine and pseudoephedrine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 6 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as desloratadine and pseudoephedrine?
9 other medicines are given the same way (oral) and in the same FDA class as desloratadine and pseudoephedrine or labeled mainly for the same use (allergies), the same class first. Allergies lists all 36 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Diphenhydramine | Allergies | 4 labelers | $0.0185 per mL 12.5 mg/5 mL | No current entry |
| Cetirizine | Allergies | 164 labelers | $0.0613 per tablet 10 mg tablet | No current entry |
| Fexofenadine | Allergies | 110 labelers | $0.230 per tablet 180 mg tablet | No current entry |
| Levocetirizine | Allergies | 53 labelers | $0.0511 per tablet 5 mg tablet | No current entry |
| Chlorpheniramine | Allergies | 2 labelers | $0.0177 per tablet 4 mg tablet | No current entry |
| Carbinoxamine | Allergies | 7 labelers | $0.398 per tablet 4 mg tablet | No current entry |
| Chlorpheniramine and ibuprofen and phenylephrine | Allergies | none listed | n/a | No current entry |
| Clemastine | Allergies | 3 labelers | $3.18 per tablet 2.68 mg tablet | No current entry |
Every medicine labeled for the same conditions as desloratadine and pseudoephedrine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to desloratadine and pseudoephedrine
- 9 medicines for the same use
- Other antihistamines
- the pharmacologic class, with prices and generics
- Desloratadine and pseudoephedrine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other